CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer
Hua Zhang,Camilla L Christensen,Ruben Dries,Matthew G Oser,Jiehui Deng,Brian Diskin,Fei Li,Yuanwang Pan,Xuzhu Zhang,Yandong Yin,Eleni Papadopoulos,Val Pyon,Cassandra Thakurdin,Nicholas Kwiatkowski,Kandarp Jani,Alexandra R Rabin,Dayanne M Castro,Ting Chen,Heather Silver,Qingyuan Huang,Mirna Bulatovic,Catríona M Dowling,Belen Sundberg,Alan Leggett,Michela Ranieri,Han Han,Shuai Li,Annan Yang,Kristen E Labbe,Christina Almonte,Vladislav O Sviderskiy,Max Quinn,Jack Donaghue,Eric S Wang,Tinghu Zhang,Zhixiang He,Vamsidhar Velcheti,Peter S Hammerman,Gordon J Freeman,Richard Bonneau,William G Kaelin Jr,Kate D Sutherland,Ariena Kersbergen,Andrew J Aguirre,Guo-Cheng Yuan,Eli Rothenberg,George Miller,Nathanael S Gray,Kwok-Kin Wong
DOI: https://doi.org/10.1016/j.ccell.2019.11.003
IF: 50.3
2020-01-13
Cancer Cell
Abstract:Cyclin-dependent kinase 7 (CDK7) is a central regulator of the cell cycle and gene transcription. However, little is known about its impact on genomic instability and cancer immunity. Using a selective CDK7 inhibitor, YKL-5-124, we demonstrated that CDK7 inhibition predominately disrupts cell-cycle progression and induces DNA replication stress and genome instability in small cell lung cancer (SCLC) while simultaneously triggering immune-response signaling. These tumor-intrinsic events provoke a robust immune surveillance program elicited by T cells, which is further enhanced by the addition of immune-checkpoint blockade. Combining YKL-5-124 with anti-PD-1 offers significant survival benefit in multiple highly aggressive murine models of SCLC, providing a rationale for new combination regimens consisting of CDK7 inhibitors and immunotherapies.